STACKD Research is educational—not medical advice. Disclaimer
Also known as: LY3298176 · dual GIP/GLP-1 agonist · Mounjaro · Zepbound
A dual GIP/GLP-1 receptor agonist (marketed as Mounjaro and Zepbound) with extensive clinical data in type 2 diabetes and obesity. Frequently compared head-to-head with semaglutide in conversations about metabolic peptides and body recomposition.
Simultaneously engages GIP and GLP-1 receptors, influencing insulin secretion, appetite, and gastric emptying. Dual agonism is thought to contribute to stronger metabolic effects than GLP-1 alone in some trials.
Large randomized trials show meaningful HbA1c and weight reductions. Evidence quality is among the strongest in the metabolic peptide class commonly discussed online.
Prescription product with labeled indications; not a research peptide for DIY use. GI adverse events, gallbladder risk signals, and muscle-loss concerns during rapid weight loss deserve diligence. Contraindications and monitoring matter.
Start with our in-house roundups—plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
2022 · human
SURMOUNT-1: substantial weight reduction vs placebo in adults with obesity.
2021 · human
Head-to-head glycemic and weight outcomes favored tirzepatide in SURPASS-2.
Commonly discussed together
Semaglutide, tirzepatide, and retatrutide are commonly compared when people research metabolic and fat-loss peptide classes—from approved GLP-1/GIP medicines to investigational triple agonists.
These are distinct molecules with different approval statuses and trial populations. Comparison talk is educational, not a recommendation to obtain or combine them.
Fat loss · Metabolic